Holen Sie sich die Stockscreener-App
15.66
1.01%
-0.16
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$15.82
Offen:
$15.66
24-Stunden-Volumen:
1.83M
Relative Volume:
1.15
Marktkapitalisierung:
$1.39B
Einnahmen:
$203.45M
Nettoeinkommen (Verlust:
$-351.45M
KGV:
-3.4418
EPS:
-4.55
Netto-Cashflow:
$-369.41M
1W Leistung:
-4.40%
1M Leistung:
+9.43%
6M Leistung:
-19.53%
1J Leistung:
+62.28%
1-Tages-Spanne:
$15.34
$15.82
1-Wochen-Bereich:
$15.34
$17.02
52-Wochen-Spanne:
$7.931
$25.29
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Vergleichen Sie TVTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
15.66 | 1.45B | 203.45M | -351.45M | -369.41M | -4.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-11 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Neutral |
| 2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-05-22 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Hold |
| 2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
| 2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Travere Therapeutics Inc. Stock Analysis and ForecastAccelerated investment success - Autocar Professional
What drives Travere Therapeutics Inc. stock priceRapidly expanding wealth - jammulinksnews.com
What analysts say about Travere Therapeutics Inc. stockConsistently exceptional gains - jammulinksnews.com
Is Travere Therapeutics Inc. a good long term investmentTriple-digit returns - Autocar Professional
Travere Therapeutics anticipates FILSPARI approval for FSGS by September 2025 - MSN
Nisa Investment Advisors LLC Trims Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Where are the Opportunities in (TVTX) - news.stocktradersdaily.com
Research Analysts Set Expectations for TVTX FY2025 Earnings - Defense World
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Teacher Retirement System of Texas - Defense World
Q2 EPS Estimates for Travere Therapeutics Lowered by Wedbush - Defense World
what makes travere therapeutics inc. stock price move sharplyTop Momentum Stock Pick - Newser
How Travere Therapeutics Inc. stock performs during market volatilityTrade With Low Risk Exposure - Newser
Why Travere Therapeutics Inc. stock attracts strong analyst attentionCapital Doubling Tips - Newser
What makes Travere Therapeutics Inc. stock price move sharplyFree Investing Community - Newser
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 11, 2025 - BioSpace
What drove TVTX's earnings growth in 2024? - AInvest
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX) - MSN
Wealth Enhancement Advisory Services LLC Invests $182,000 in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
(TVTX) Proactive Strategies - news.stocktradersdaily.com
Travere Therapeutics (NASDAQ:TVTX) and Ensysce Biosciences (NASDAQ:ENSC) Head to Head Comparison - Defense World
Travere Therapeutics: A Rare Gem in Kidney Disease Therapies - AInvest
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.TVTX - PR Newswire
Travere Therapeutics, Inc.(NasdaqGM: TVTX) added to Russell 2000 Growth Index - MarketScreener
Travere Therapeutics Draws Institutional Interest from Armistice Capital, Driehaus, and Wellington - International Business Times
High-Growth Tech Stocks in Biopharma and Networking: Undervalued Gems with Strong Upside - AInvest
Travere Therapeutics Kicks Off “Play It Forward” Campaign for FSGS Awareness - Insider Monkey
Travere Therapeutics asks FSGS patients to Play It Forward - Medical Marketing and Media
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere ... - Bluefield Daily Telegraph
(TVTX) On The My Stocks Page - news.stocktradersdaily.com
Rhumbline Advisers Grows Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):